Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind Study to Compare the Durability of Glucose Lowering and Preservation of Pancreatic Beta-Cell Function of Rosiglitazone Monotherapy Compared to Metformin or Glyburide/Glibenclamide in Patients With Drug-Naive, Recently Diagnosed Type 2 Diabetes Mellitus
Conditions
Interventions
Rosiglitazone
glyburide
+1 more
Locations
490
United States
GSK Investigational Site
Anniston, Alabama, United States
GSK Investigational Site
Birmingham, Alabama, United States
GSK Investigational Site
Mesa, Arizona, United States
GSK Investigational Site
Tucson, Arizona, United States
GSK Investigational Site
Little Rock, Arkansas, United States
GSK Investigational Site
Berkeley, California, United States
Start Date
January 3, 2000
Primary Completion Date
June 1, 2006
Completion Date
June 19, 2006
Last Updated
November 29, 2017
NCT06513026
NCT07112339
NCT06329375
NCT06945406
NCT06959901
NCT06574035
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions